tert-butyl 3-((4-(benzo[d]thiazol-2-yl(methyl)amino)piperidin-1-yl)methyl)-9-azabicyclo[3.3.1]non-2-ene-9-carboxylate | 1011533-13-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: tert-butyl 3-((4-(benzo[d]thiazol-2-yl(methyl)amino)piperidin-1-yl)methyl)-9-azabicyclo[3.3.1]non-2-ene-9-carboxylate
• CAS: 1011533-13-3
• 化学式: C₂₇H₃₈N₄O₂S
• 分子量: 482.69
• InChiKey: LPSCSUOSNHWFFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.69
• 重原子数：
  34.0
• 可旋转键数：
  4.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  48.91
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-((4-(benzo[d]thiazol-2-yl(methyl)amino)piperidin-1-yl)methyl)-9-azabicyclo[3.3.1]non-2-ene-9-carboxylate 在 盐酸 作用下， 以 甲醇 为溶剂， 以100%的产率得到
  参考文献：
  名称：

  Development of CXCR3 antagonists. Part 4: Discovery of 2-amino-(4-tropinyl)quinolines

  摘要：

  The synthesis and biological evaluation of a novel series of 2-aminoquinoline substituted piperidines and tropanes incorporating a homotropene moiety is herein described. The series exhibits potent antagonism of the CXCR3 receptor and superior physicochemical properties. Compound 24d was found to be orally bioavailable, and PK/PD studies suggested it as a suitable tool for studying the role of CXCR3 in models of disease. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.075
• 作为产物：
  描述：

  tert-butyl 3-formyl-9-azabicyclo[3.3.1]non-2-ene-9-carboxylate 、 N-methyl-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine 在 三乙酰氧基硼氢化钠 、 N,N-二异丙基乙胺 、 原甲酸三甲酯 作用下， 以 二氯甲烷 为溶剂， 以65%的产率得到tert-butyl 3-((4-(benzo[d]thiazol-2-yl(methyl)amino)piperidin-1-yl)methyl)-9-azabicyclo[3.3.1]non-2-ene-9-carboxylate
  参考文献：
  名称：

  Development of CXCR3 antagonists. Part 4: Discovery of 2-amino-(4-tropinyl)quinolines

  摘要：

  The synthesis and biological evaluation of a novel series of 2-aminoquinoline substituted piperidines and tropanes incorporating a homotropene moiety is herein described. The series exhibits potent antagonism of the CXCR3 receptor and superior physicochemical properties. Compound 24d was found to be orally bioavailable, and PK/PD studies suggested it as a suitable tool for studying the role of CXCR3 in models of disease. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.075